Funded Startups in Montpellier
Among the 22 most recent Montpellier-funded rounds shown, one disclosed amount stands apart: Qair’s $83M on 2023-08-07.
Among the 22 most recent Montpellier-funded rounds shown, one disclosed amount stands apart: Qair’s $83M on 2023-08-07. The next-highest disclosed rounds cluster in a different band (e.g., Plug In Digital $75M on 2021-11-24, Sweep $73M on 2022-04-04, and Elements $54M on 2023-12-07), while several others sit at $23M or below (such as SeqOne Genomics $23M on 2025-05-22 and AI-Stroke $5M on 2025-11-22).
The list also clusters temporally across multiple peaks rather than a single continuous surge: late 2024 has several entries (PimpUp $2M on 2024-11-15; CILcare $22M on 2024-12-04; SCOP3 $6M on 2024-05-16), and a concentration appears again in 2021–2022 with several $47M–$75M rounds (Quantum Surgical $47M on 2021-10-19; Plug In Digital $75M on 2021-11-24; Sweep $73M on 2022-04-04). Sector-wise, Health Care and Artificial Intelligence/AI repeatedly recur across the top of the list (e.g., AI-Stroke $5M on 2025-11-22; CILcare $22M on 2024-12-04; Quantum Surgical $47M on 2021-10-19; Celest Science $2M on 2025-04-22).
Most recent rounds
22 shownRelated listings
Frequently asked
What is the largest disclosed round in this Montpellier set, and is it an outlier versus the rest of the disclosed amounts?
Qair’s $83M (2023-08-07) is the highest disclosed amount in the 22-row list; the next-largest disclosed rounds are lower and grouped (Plug In Digital $75M on 2021-11-24, Sweep $73M on 2022-04-04, Elements $54M on 2023-12-07).
Do rounds cluster in a tight recent window, or are they spread out across years?
The span runs from 2021-02-18 (AcuSurgical $7M) through 2025-11-22 (AI-Stroke $5M), indicating multi-year coverage rather than a single short campaign. Still, there are dense periods: multiple large rounds appear in 2021–2022 (Quantum Surgical $47M on 2021-10-19; Plug In Digital $75M on 2021-11-24; Sweep $73M on 2022-04-04).
Which entry is the most recent, and how does its disclosed amount compare to the list’s upper range?
The most recent dated row is AI-Stroke at $5M on 2025-11-22. That $5M level is far below the disclosed upper range in this set, where Qair reaches $83M on 2023-08-07 and Plug In Digital reaches $75M on 2021-11-24.
Is there a stage classification pattern in the disclosed rounds, or are 'Series Unknown' rounds common?
Several rows use 'Series Unknown' rather than a named stage (e.g., SeqOne Genomics $23M on 2025-05-22; Mabqi $5M on 2025-02-26; Elements $54M on 2023-12-07; Qair $83M on 2023-08-07; Sweep is the exception as it is labeled Series B at $73M on 2022-04-04). Named-stage examples also include Seed (AI-Stroke $5M on 2025-11-22; Celest Science $2M on 2025-04-22) and Series A (CILcare $22M on 2024-12-04; Bfore.AI $15M on 2024-04-24).
Are any sectors over-represented across the 22 rows?
Health Care appears repeatedly (AI-Stroke is tagged Healthcare; CILcare $22M on 2024-12-04; Quantum Surgical $47M on 2021-10-19; AcuSurgical $7M on 2021-02-18; Intrasense SA has $6M on 2021-06-23). Artificial Intelligence/AI also shows up multiple times near the top (AI-Stroke $5M on 2025-11-22; Celest Science $2M on 2025-04-22; Bfore.AI $15M on 2024-04-24).
Which entries are smallest by disclosed amount, and do they sit in the same stage/sector bands as the biggest rounds?
The smallest disclosed amount shown is $540K, appearing for Deepbloo ($540K on 2024-06-18) and for PeopleSpheres ($540K on 2023-09-06). These low-disclosed rounds are substantially below the highest disclosed amounts such as Qair $83M (2023-08-07), and they occur in different sector labels (Deepbloo is Information Technology; PeopleSpheres is Administrative Services) rather than the Health Care/AI labels that recur in many of the higher disclosed deals (e.g., CILcare $22M on 2024-12-04; Bfore.AI $15M on 2024-04-24).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.